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1. Introduction 
Many cancer patients will first present to a primary care provider either in the clinic or 
acutely in the inpatient setting before a definite diagnosis of cancer is made. Thus, an 
accurate clinical evaluation - through history taking and physical examination - by a 
general practitioner could reveal malignant diseases at their early stages. In some 
instances, cancer is incidentally detected while a patient is being treated for other 
unrelated diseases. Plain radiographs ordered by the primary care physician for 
pneumonias or back pains, for instance, have been known to reveal occult lung tumors or 
bone metastasis. 
With advances in cancer treatment, many cancer patients are living into the survivorship 
period and are increasingly being seen by primary care providers following active 
treatment. At such times, the primary care provider plays a major role in surveillance, 
management of cancer treatment complications and treatment of comorbid conditions. A 40 
year old woman who has been treated for breast cancer, for example, will still need 
colorectal cancer screening as well as yearly pap smears from her primary care physician in 
addition to her required follow up with Breast Oncology. 
Since the primary care provider plays such an invaluable role in cancer prevention, 
detection and control, it is imperative that the primary care provider is kept abreast of the 
latest advances in the ever evolving field of cancer diagnosis and therapy. While the general 
practitioner will likely not be responsible for cancer staging and treatment, there might be 
need for him or her to select the initial screening or diagnostic tests for malignant diseases 
prior to referral to the cancer specialist. There is therefore need for a concise literature for the 
generalist on the current and up-to-date approach to the diagnosis and treatment of cancers 
and hematological diseases. 
Current classifications in surgical pathology for staging malignancies are based on anatomic 
features (tumor-node-metastasis) and histopathology (grade)1. Different modalities 
currently exist for the diagnosis and treatment of cancer. Most have been in use for many 
years whereas others have evolved as our understanding of the molecular processes that 
lead to carcinogenesis has increased. 
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2. Laboratory diagnosis of hematological and oncological diseases  
2.1 Morphological methods 
Morphological examinations are the easiest methods of cancer diagnosis.2 Many 
sophisticated laboratory and imaging techniques have evolved in Oncology over the years 
but clinician still have to depend on histopathology for the definite diagnosis of many solid 
tumors. Only in rare occasions have imaging and appropriate biochemical assays 
substituted microscopic examination of a tissue sample for cancer diagnosis. 
Proper pathological diagnosis begins with the referring clinician. Since certain disease 
processes share similar morphological and microscopic appearances, the clinical information 
supplied by the requesting medical provider goes a long way in helping the histopathologist 
to make definitive diagnoses. Proper and complete history must precede all requests for 
pathological evaluation.  
Pertinent patient data that must accompany any tissue sample to the laboratory include the 
patient identity, age, gender, duration of the disease and exact location of the lesion, size 
and any previous treatment. With the advent of electronic medical records, the clinician 
should ensure that these data are in the patient’s electronic records from where the 
pathologist can retrieve them easily as needed. 
In addition to appropriate collection and reporting of clinical data to the pathologist, the 
referring physician must ensure that the pathological specimen is properly obtained from 
a well selected biopsy site and must be properly handled and transported to the 
laboratory.  
2.2 Sampling methods for pathological exam 
Incisional biopsy is easy to perform. It involves the removal of a small part of a large tumor 
for the purpose of laboratory diagnosis. This method is usually chosen for lesions that are 
easy to access. Following diagnosis, the tumor is usually completely removed surgically or 
treated by other modalities. 
Excisional biopsy is an alternative to incisional biopsy. It enables a more complete 
pathological exam of the lesion and thus it is the most appropriate collection method for 
small tumors. It is also the best method for evaluation of lymph nodes; since pathological 
changes in lymph nodes may be focal and might be missed when sampled by incisional 
biopsy3 . As expected, excisional biopsy might cause more local trauma than incision biopsy. 
Needle aspiration allows the clinician to obtain a core of tissue from a mass for cytological 
examination. It is increasingly being employed for tumors in which there is a visible or 
readily palpable mass such as lymph nodes, breast or thyroid. Using ultrasound, computed 
tomography or fluoroscopy guidance, needle aspiration can also be used for deeper organs 
such as the liver. There is a possible complication of tumor implantation along the tract of 
the needle. 
Cytology is a method that has been used widely in cervical cancer screening and could be 
employed for other suspected cancers like bladder, gastric and lung cancers. It is based on 
the premise that neoplastic cells are less cohesive than normal cells and are easily shed into 
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body fluids such as urine, gastric fluid, pleural, peritoneal and bronchial fluids.2 With 
improvement in accessibility of organs by endoscopy, cytological examinations are being 
largely replaced by direct endoscopy and biopsy of the stomach, bladder, and bronchi.3 
Cytology may still be used in follow up of patients that have been treated for cancers of the 
bladder or urinary tract. Routine Papanicolaou smears are still the mainstay of cervical 
cancer screening. 
Endoscopic procedures grant access to internal organs thereby enabling biopsy of the internal 
organs 
2.3 Specimen preparation 
Following collection of tissue specimen, it undergoes preparation prior to histological exam. 
Specimen preparation can be permanent or frozen sections. 
Permanent method involves the processes of fixation, embedding, sectioning and staining. 
The tissue specimen is initially fixed in formalin, and then embedded in paraffin wax to 
preserve its architecture and facilitate sectioning. Sectioning involves cutting the specimen 
into thin slices that can be examined with the microscope. The micro-sections are then 
finally stained prior to microscopic examination.  
When the pathologist anticipates a different examination modality than histopathology, the 
choice of fixing and staining agents might be modified as appropriate. 
Frozen section is a rapid method that quickly prepares fresh tissue for microscopic 
examination. It is easily used by surgeon within the operating suite to obtain an immediate 
pathological interpretation of the specimen and thus decide on the next therapeutic 
approach to pursue during surgery. It has also enabled surgeons to establish adequacy of 
excision margins.3 
2.4 Molecular techniques 
The diversity of genomic alterations involved in malignancy had led to the development of 
a variety of assays for complete tumor profiling. Thus, it is no longer adequate to know the 
histopathology of a cancer. The new molecular diagnostics when integrated into existing 
histomorphological classifications in surgical pathology provides additional stratification for 
a more accurate cancer prognosis.1 
Detection of molecular markers in neoplastic tissue samples can be used to provide accurate 
diagnosis, prognosis and prediction of response, resistance, or toxicity to therapy. These 
molecular markers can be products of altered genes/DNA or abnormal pathways. 
Mutations in DNA can include rearrangements such as translocations, inversions, gene 
amplifications/deletions, point mutations and base insertions/deletions.  
Cytogenetic procedures study the chromosomes in the tissue sample with the aim to 
identify any chromosomal changes that are peculiar to known cancer types. 
FISH technique is a molecular cytogenetic technique in which probes are used to confirm 
presence or absence of specific DNA sequences on chromosomes. It is used in diagnosis of 
blood disorders or cancer which are due to specific genetic alterations on the chromosomes.  
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PCR is a quantitative technique that permits amplification and analysis of target DNA 
regions in tumor samples. 
DNA microarray analysis is equipped to measure the expression levels of large number of 
genes concurrently. 
Immunocytochemistry (IHC)is used to detect antigens or protein expression on a fixed tissue 
section by means of an antibody that is specific for the antigen/protein. The antibody-
antigen reaction is visualized by linking the antibody to an enzyme that catalyzes a color 
producing reaction or to a substance that fluoresces. IHC serves as an adjunct to regular 
histological exam of a tissue sample and is being routinely used to detect the presence of 
antigens, proteins, and biomarkers in neoplastic tissue samples. It has been employed 
largely for the detection of estrogen and progesterone receptors on breast tissues, to detect 
oncogenes and tumor suppressor gene products on tumor samples as well as to characterize 
leukemias and lymphomas. 
Flow cytometry is a technique that is used to examine and differentiate cells based on certain 
physical and chemical properties. A sample of blood or tissue cells in suspension is passed 
through the flow cytometer and the scatter emitted by the cell where it meets the light is 
analyzed to better characterize the cell.  
Electron microscopy is used when specific cellular or intracellular structures need to be 
examined. Like IHC, it aids in a more accurate tumor classification. 
Molecular cancer diagnostic techniques have been instrumental to identifying the brc-abl in 
CML, HER-2/NEU expression in breast cancer. 
2.5 Biomarkers 
Biomarkers are proteins which are released from cancers and whose detection or increase in 
the serum may screen or confirm the presence of certain cancers. Biochemical assays for 
tumor-associated enzymes, hormones and other markers are not being used for the 
definitive diagnosis of cancer2. Instead, cancer biomarkers complement pathological 
examination and thus play a role in the early detection, outcome prediction and detection of 
disease recurrence. In addition, in the present era of new therapeutic agents, biomarkers can 
help to determine which tumors will respond to which treatments.4 Some biomarkers that 
are currently in clinical use are shown in Table 1. 
The ideal biomarker should have a high specificity and sensitivity, especially if it is to be useful 
for staging 5. In addition, it should be easily detected in the patient’s blood or urine but not in a 
healthy person. Many of the current biomarkers in clinical practice lack enough sensitivity or 
specificity to accurately serve as the sole diagnostic tool for the diagnosis of any cancer. 
It must be pointed out that despite the detection of biomarkers in a patient, a histological 
exam is often necessary to confirm cancer. 
3. Imaging diagnosis 
Histological diagnosis is still essential to establish the diagnosis of cancer. But a well-
designed imaging strategy is important in the management of a patient with cancer. 
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Depending on circumstances, imaging can precede or follow histopathology.6 The choice of 
imaging techniques are many and still evolving, and the physician must carefully select the 
modalities based on a good understanding of the specific neoplasm, its biological 
characteristics and its response to treatment.7 
 
Adapted from Ludwig JA, Weinstein JN. 2005. Biomarkers in cancer staging, prognosis and selection. 
Nature Reviews Cancer 5 : 845-857. 
Table 1. Examples of common biomarkers in clinical use 
Imaging in Oncology is used for screening, detection, diagnosis, treatment and to follow 
response to treatment. The choice of imaging for every type of cancer is beyond the scope of 
this text. Brief highlights of each of the commonly available imaging modalities will be 
enumerated. 
Conventional radiology is widely available, and cheap. It is however largely being replaced 
by other techniques like CT and MRI for definition of tumor anatomy. Plain and Contrast 
radiography (barium or iodine) is still part of initial evaluation of GI pathology.7 Many 
cancers have been discovered following radiological tests done for unrelated diseases. 
Ultrasound US is relatively cheap and safe. It has become instrumental in guiding 
procedures such as biopsies and for assessment of fluid collections. 
Mammography has become routine for breast cancer screening. This is the commonest 
imaging technique that is being used for mass screening for cancer. 
CT plays a critical role in cancer diagnosis, staging, follow up as well as in relapse of 
neoplastic disease. It is increasingly being used to guide diagnostic biopsies, as part of 
radiotherapy simulations. 
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MRI is a costly imaging method. Like CT, it is useful in diagnosis, staging, therapy and 
follow up. It is also increasingly being used in minimally invasive procedures. CT is 
however more widely available. 
PET makes use of labeled isotopes active which are tagged to metabolically active 
substances. When such substances are administered, they concentrate on certain areas of the 
body and yield imaging studies of metabolism. PET is useful in staging, detecting 
recurrences and evaluation of several cancers such as head and neck tumors, brain tumors, 
lymphomas, and colorectal cancers. 
The last decade has seen the gradual shift to PET/CT which is an imaging modality that 
combines anatomy and function. It has become a powerful tool for diagnosis and staging in 
Oncology. PET-CT combines the functional imaging obtained by PET to the anatomical 
imaging of CT to a single superimposed image. The patient is therefore saved the time and 
costs of two separate imaging sessions. Even though this imaging technique was initially 
used for lung cancers, it is fast becoming a standard for most other cancers. MR and MR 
spectrometry are other imaging modalities that could potentially be fused with molecular 
PET techniques.8 
Many other newer techniques such as magnetic resonance spectroscopy, impedance 
tomography, and laser optical tomography are increasingly being studied for application to 
cancer imaging.6 
4. Cancer therapy  
Surgery, radiation and chemotherapy are the oldest treatment modalities for malignancies. 
From the time cancer is first suspected or diagnosed, there is need for the different cancer 
disciplines to work together to formulate the best treatment plan for the patient. Since each 
patient and each cancer is different, treatment must be individualized. The exact treatment 
choice or combination of choices will depend on the patient, the disease and the stage of the 
disease as well as other considerations such as performance status, and comorbid conditions. 
4.1 Pharmacotherapy 
Cytotoxic agents still form the basis of many cancer therapy regimens. The growth pattern 
of individual neoplastic cells may greatly affect the overall behavior of tumors and their 
responses to specific types of cancer therapy.  
The cell cycle gives us an insight into the kinetic behavior of dividing cells.9 The four distinct 
phases of the cell cycle are: G1, G2 ,S and M phases. G1 is a stage of cell increase or growth. 
This is followed by DNA replication or synthesis during the S (synthesis) phase. G2 is 
another stage of cell growth. During the M (mitosis) stage, the cell growth is halted while 
active division takes place. During the G1 and G2 phases, the cellular constituents are 
synthesized. The cell cycle is well regulated with checkpoints that ensure that cells moved 
into the next cell cycle phase only after the proceeding phases are well completed. These 
checkpoints may become abnormal in cancer. 
Some cytotoxics act at specific points in the cell cycle. Antimetabolites are more active 
against the S-phase cells while the vinca alkaloids and taxols are more M-phase specific. 
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Alkylating agents and platinum derivatives are cell-cycle-nonspecific agents. Fig 1 and 
Table 2 list some chemotherapeutic agents in common use and their mechanisms of action.  
 
Fig. 1. Action of selected chemotherapeutic agent. 
Chemotherapeutic agents are used as primary treatment for advanced disease, as 
neoadjucant to surgery/ radiation for localized disease or as adjuvant therapy (with surgery 
and/or radiation). In addition to systemic administration, anticancer agents can also be 
delivered regionally. Classical examples of regional delivery of chemotherapy include 
intrathecal administration of methothrexate in the treatment and prevention of meningeal 
leukemia, intraperitoneal chemotherapy in management of ovarian cancer, intravesical 
treatment for superficial bladder cancer, and intrahepatic arterial therapy for colon cancer 
metastatic to the liver.10  
4.2 Target cancer therapies 
Recent advances in genetics and molecular cellular biology has led to exponential increase 
in our understanding of the molecular events that either initiate or sustain cancer growth. 
Whereas traditional chemotherapeutic agents may not differentiate between normal and 
cancer cells, the newer biological agents target specific molecular pathology (pathways and 
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aberrant genes)in cancer cells.11 Target therapeutics can be monoclonal antibodies or small 
molecules. They can be used alone or in combination with other chemotherapeutics, surgery 
or radiation therapy. 
4.3 Monoclonal antibodies 
Monoclonal antibodies are antibodies that bind to antigens found specifically on cancer cells 
and thus induce an immune reaction against the cancer cells. These antigens are usually 
extra-cellular proteins or cell surface antigens that are expressed specifically by the 
neoplastic cells. 
Many monoclonal antibodies have been produced and find use in treatment of autoimmune 
and oncological disorders. Their names usually end in the letters –mab-short for monoclonal 
antibodies.(Table 3) Some antibodies are already approved for clinical use whereas many 
others are still experimental and undergoing clinical trials. 
4.4 Small molecules 
By virtue of their size, small molecules can reach intracellular sites where they act to interact 
with molecular pathways and exert anti-tumor effects. Table 4 enumerates some of the 
small molecules that are currently in clinical use. 
4.5 Endocrine therapy 
Use of hormones in Oncology is based on the recognition that some human cancers undergo 
changes following fluctuations in certain sex hormones. Hormone deprivation can be achieved 
by surgical removal of the steroid gland or by administration of inhibitors of the hormone 
biosynthesis. Examples of hormonal therapy for cancers include use of antiestrogens and 
LHRH analogues for breast cancer as well as use of antiandrogens and LHRH analogues for 
prostate cancer. Steroids (prednisone, dexamethasone) are used either alone or in combination 
with other cytotoxic agents for the treatment of leukemias, lymphomas and multiple 
myelomas. Steroids are also used in the management of hypercalcemia as well as for the tissue 
swelling that accompanied tumors of the lungs and the airway obstruction. 
 
Alkylating agents 
Bendamustine, cyclophospham, chlorambucil, ifosfamide, carmustine, lomustine, 




Methotrexate, pemetrexed, fludarabine, mercaptopurine, thioguanine, cladribine, 
pentostatin, capecitabine, cytarabine, floxuridinefluorouracil, gemcitabine, hydroxyurea 
 
Natural products 
Bleomycin, dactinomycin, daunorubicin, doxorubicin, doxil, epirubicin, idarubicin, 
mitomycin, etoposide, teniposide, docetaxel, paclitaxel, vinblastine, vincristine, 
vinorelbine, irinotecan, topotecan, asparaginase 
Table 2. Chemotherapeutic agents 
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4.6 Radiation therapy  
Radiation therapy is the administration of ionizing radiation to a cancer patient for the 
purpose of cure, palliation or as an adjunct to surgical treatment. Confirmation of 
malignancy by pathological exam, ancillary workup and staging must be completed prior to 
radiation therapy. 
Radiation therapy is often used in conjunction with surgery for eradication of small, limited 
human cancers. Preoperatively, radiation therapy may be given to shrink inoperable tumors 
or to destroy unrecognized peripheral projections of the tumor. This method is applicable to 
advanced tumors of the head and neck, colorectum and bladder. On the other hand, 
radiation therapy can be given post operatively to eradicate residual disease or to control 
subclinical disease in the wound or in the lymphnodes.12 
Radiation therapy is also used for palliation in instances like cancers of the central nervous 
system and pathological metastasis to the bones  
4.7 Surgery  
Surgery plays vital role in the prevention, diagnosis, staging, cure and palliation. Many 
premalignant lesions are usually surgically removed to prevent progression to cancer. 
Family members with familial polyposis of the colon for example, are routinely being 
offered colectomy to prevent eventual development of colon cancer. Mastectomy can also be 
done prophylactically for patients at high risk for breast cancer following the appropriate 
genetic counseling. 
Incisional, excisional and needle biopsy techniques as well as endoscopy are surgical 
methods that aid cancer diagnosis. 
Surgery forms the basis of therapy for early cancer in which case it is employed as local treatment 
for small tumors, to reduce the bulk of the disease, and for removal of metastatic tumors. 
Even though late stage cancers are mainly treated by chemotherapy, surgery could offer 
palliation in advanced cancers. Typical examples of such instances include stenting for 
biliary obstruction due to advanced tumors of the biliary system or for esophageal 
obstruction.  
4.8 Gene therapy 
Cancer gene therapy is anchored on the premise that many cancers are due to genetic 
alterations that eventually lead to malignant changes in tissues. Gene therapy involves the 
transfer of genetic material into a cell to alter the cellular phenotype transiently or 
permanently. Gene transfer can be performed in vitro or in vivo. Different vectors exist for 
gene delivery into cancerous cells. Viruses (such as retroviruses) serve as a perfect tool for 
gene transfer. Gene therapies for cancer treatment are evolving and are largely still 
undergoing studies. 
5. Conclusion 
The general practitioner will see cancer patients at one time or the other in the course of 
their disease. Even though the primary care practitioner is not a medical, surgical or radio-
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oncologist, he is part of the interdisciplinary team that is crucial for provision of optimal 
care for the cancer patient or cancer survivor. Burdened with such a responsibility, the 
general practitioner must keep abreast of the available screening, diagnostic and therapeutic 
modalities that currently exist for malignant diseases. Surgery, radiation and chemotherapy 
still play a large role in the treatment of cancer. But with advances in molecular biology and 
individualized medicine, many new diagnostic and treatment options are gradually shifting 
towards identifying and treating cancer at the level of the genes or molecular pathways. The  
 
 
Agent        Molecular target   Disease indication  
 
Trastuzumab(Herceptin)   ERBB2   Breast cancer 
Bevacizumab(Avastin)   VEGFR   Metastatic colorectal cancer 
Cetuximab (Erbitux)  EGFR   Metastatic colorectal cancer 
Alemtuzumab(Campath)   CD52   B-cell Chronic lymphocytic  
       leukemia 





Drug    Molecular target   Uses/Disease indication 
 
Bortezomib   26S proteosome  Multiple myeloma 
Dasatinib  brc-abl,PDGFR  CML, Philadelphia positiveALL 
Erlotinib  HER1/EGFR  NCSLC ,pancreas 
Gefitinib  EGFR   NSCLC 
Imatinib   brc-abl,PDGFR  CML,GIST 
Lapatinib  EGFR,HER2  HER-2 positive metastatic breast  
      cancer 
Nilotinib   brc-abl,PDGFR  CML 
Sorafenib  VEGFR,PDGFR,RAF-1 renal cell cancer 
Sunitinib  VEGFR,PDGFR,RET,c-kit renal cell cancer, GIST 
Temsirolimus  mTOR   renal cell cancer 
Modified from Cancer management: A multidisciplinary approach. 11th ed. Lawrence,Kansas: CMPMedica.  
Table 4. Targeted cancer therapeutics: small molecules 
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primary care provider will therefore increasingly encounter patients that are being treated 
with these new cancer therapies. Stem cell and genetic therapies as well as some target 
therapies are still evolving and over the next few years will find their way into our 
therapeutic regimens. 
6. Abbreviations 
ALL   acute lymphoblastic leukemia 
AML  acute myeloid leukemia 
BTA   bladder tumor antigen 
CML   chronic myelogenous leukemia 
CT   computed tomography 
BCR-ABL  oncogene fusion protein associated with the Philadelphia chromosome 
EGFR   epidermal growth factor receptor 
HER2-NEU  human epidermal growth factor receptor 2 
DNA   deoxyribonucleic acid 
FISH   fluorescence in situ hybridization  
GIST   gastrointestinal stromal tumor 
IHC   immunohistochemistry 
MRI   magnetic resonance imaging 
PET  positron emission tomography 
PET-CT   positron emission tomography-computed tomography 
VEGFR   vascular endothelial growth factor receptor 
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